ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2187

Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Abstract Number: 2188

The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Abstract Number: 2189

Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study
Abstract Number: 2190

Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis
Abstract Number: 2191

Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
Abstract Number: 2192

Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Abstract Number: 2193

Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Abstract Number: 2194

Is Vaccination Against Covid-19 Associated with Autoimmune Rheumatic Disease Flare? Self-controlled Case Series Analysis Using Data from the Clinical Practice Research Datalink (Aurum)
Abstract Number: 2195

Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases
Abstract Number: 2196

Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Abstract Number: 2197

Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
Abstract Number: 2198

How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Abstract Number: 2199

Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Abstract Number: 2200

Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare
Abstract Number: 2201

Increased Economic Burden of Uveitis Among Patients with Psoriasis and Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2022

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].